AbbVie Inc
For the period ended Dec 31, 2023. Filed Feb 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 20, 2024
ABBV$293.30+0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Equity
| years ended December 31 (in millions) | Common shares outstanding | Common stock | Treasury stock | Additional paid-in capital | Retained earnings (accumulated deficit) | Accumulated other comprehensive loss | Noncontrolling interest | Total |
|---|---|---|---|---|---|---|---|---|
| Balance at December 31, 2020 | 1,765 | $18 | $(2,264) | $17,384 | $1,055 | $(3,117) | $21 | $13,097 |
| Net earnings attributable to AbbVie Inc. | — | — | — | — | 11,542 | — | — | 11,542 |
| Other comprehensive income, net of tax | — | — | — | — | — | 218 | — | 218 |
| Dividends declared | — | — | — | — | (9,470) | — | — | (9,470) |
| Purchases of treasury stock | (8) | — | (934) | — | — | — | — | (934) |
| Stock-based compensation plans and other | 11 | — | 55 | 921 | — | — | — | 976 |
| Change in noncontrolling interest | — | — | — | — | — | — | 7 | 7 |
| Balance at December 31, 2021 | 1,768 | 18 | (3,143) | 18,305 | 3,127 | (2,899) | 28 | 15,436 |
| Net earnings attributable to AbbVie Inc. | — | — | — | — | 11,836 | — | — | 11,836 |
| Other comprehensive income, net of tax | — | — | — | — | — | 700 | — | 700 |
| Dividends declared | — | — | — | — | (10,179) | — | — | (10,179) |
| Purchases of treasury stock | (10) | — | (1,487) | — | — | — | — | (1,487) |
| Stock-based compensation plans and other | 11 | — | 36 | 940 | — | — | — | 976 |
| Change in noncontrolling interest | — | — | — | — | — | — | 5 | 5 |
| Balance at December 31, 2022 | 1,769 | 18 | (4,594) | 19,245 | 4,784 | (2,199) | 33 | 17,287 |
| Net earnings attributable to AbbVie Inc. | — | — | — | — | 4,863 | — | — | 4,863 |
| Other comprehensive loss, net of tax | — | — | — | — | — | (106) | — | (106) |
| Dividends declared | — | — | — | — | (10,647) | — | — | (10,647) |
| Purchases of treasury stock | (12) | — | (1,978) | — | — | — | — | (1,978) |
| Stock-based compensation plans and other | 9 | — | 39 | 935 | — | — | — | 974 |
| Change in noncontrolling interest | — | — | — | — | — | — | 4 | 4 |
| Balance at December 31, 2023 | 1,766 | $18 | $(6,533) | $20,180 | $(1,000) | $(2,305) | $37 | $10,397 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.